Cargando…

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

This cross-sectional study evaluates the prevalence of proton pump inhibitor use among patients with cancer at 4 French comprehensive cancer centers.

Detalles Bibliográficos
Autores principales:	Raoul, Jean-Luc, Guérin-Charbonnel, Catherine, Edeline, Julien, Simmet, Victor, Gilabert, Marine, Frenel, Jean-Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209575/ https://www.ncbi.nlm.nih.gov/pubmed/34132796 http://dx.doi.org/10.1001/jamanetworkopen.2021.13739

Ejemplares similares

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
por: Raoul, Jean-Luc, et al.
Publicado: (2022)

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
por: Raoul, J.L., et al.
Publicado: (2023)

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2019)

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses
por: Jézéquel, Pascal, et al.
Publicado: (2013)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
por: Moreau-Bachelard, Camille, et al.
Publicado: (2022)

Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers
por: Bocquet, François, et al.
Publicado: (2023)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
por: Raoul, Jean-Luc, et al.
Publicado: (2014)

Proton-pump inhibitors should be strictly prescribed in clinic
por: Yang, Xuesong, et al.
Publicado: (2022)

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
por: Zirk-Sadowski, Jan, et al.
Publicado: (2017)

Deprescribing in older people: helpful tools and proton pump inhibitors
Publicado: (2020)

Exploration of Proton Pump Inhibitors Use During Pregnancy and Preeclampsia
por: Choi, Ahhyung, et al.
Publicado: (2021)

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors
por: Duan, Zhihui, et al.
Publicado: (2022)

New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
por: Edeline, Julien, et al.
Publicado: (2022)

Effect of proton pump inhibitor use on Helicobacter pylori positivity and atrial fibrillation
por: Atay, Kadri, et al.
Publicado: (2015)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections
por: Price, Elizabeth, et al.
Publicado: (2021)

Increased Proton Pump Inhibitors−Induced Mortality Risk in Hemodialysis Patients
por: Sertorio, Jonas T., et al.
Publicado: (2018)

The costly case of proton-pump inhibitors: a single-center experience
por: Suresh Kumar, Vishnu Charan, et al.
Publicado: (2020)

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
por: Homolak, Jan, et al.
Publicado: (2021)

Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients
por: Rodriguez-Alonso, Lorena, et al.
Publicado: (2018)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

The Necessity of Validated Questionnaires: Determining Accurate Responses to Proton Pump Inhibitor Use
por: Jung, Kee Wook
Publicado: (2012)

High or Nonhigh Doses of Proton Pump Inhibitors for Patients with Peptic Ulcer Bleeding?
por: Hsieh, Yu-Hsi, et al.
Publicado: (2013)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

IgE-mediated allergy to proton pump inhibitors with both delayed and immediate onset
por: Barakat, Leyla, et al.
Publicado: (2019)

Bazex Syndrome Revealing a Gastric Cancer
por: Robert, Maxime, et al.
Publicado: (2014)

Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers
por: de Vries, F., et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease
por: Hughes, John, et al.
Publicado: (2018)

Does Helicobacter pylori eradication or proton pump inhibitor use benefit gastroesophageal reflux disease?
por: Sakin, Yusuf Serdar, et al.
Publicado: (2015)

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis
por: Savarino, Edoardo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_afp5j6bghvmjof4jfd2tot977r